ClinicalTrials.gg
Active, not recruitingNCT06412666CEDAR-HCMUpdated Aug 18, 2026

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

A Phase 2/3 interventional study of Aficamten and Placebo in Pediatric and Symptomatic Obstructive Hypertrophic Cardiomyopathy, sponsored by Cytokinetics. Active, not recruiting at 36 sites in 6 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Cytokinetics · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic — 2 open to participants now, 5 under way, 4 of them phase 3. aficamten · Cardiomyopathy, Hypertrophic.

Planned enrollment
7th of 11
65 · median 96
Started
2024
the only one that year
Phase 2/3
2 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
7 of 11
Cytokinetics

Among the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 2 in phase 2/3, and was the 9th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

2 of the 11 studies testing aficamten in Cardiomyopathy, Hypertrophic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aficamten

aficamten: first FDA approval 2025 (MYQORZO), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing aficamten in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Read the detailed description

The overall objective of the trial is to determine the efficacy, safety, and tolerability of administration of aficamten in adolescents (12 to \< 18 years old) and children (6 to \< 12 years old) with symptomatic oHCM. Adolescents and children will be studied in a staged approach involving established favorable pharmacodynamic and safety profiles of aficamten in adolescents followed by further pharmacokinetic modeling to inform the dosing regimen in children.

The 12 to \<18 years old cohort has enrolled all participants and is no longer recruiting, the 6 to \< 12 year old cohort is not yet recruiting.

The trial will consist of 3 periods:

  1. Period 1 is the randomized, double-blind, placebo-controlled treatment period that will assess the efficacy, safety and tolerability of aficamten in pediatric participants.
  2. Period 2 is the open-label extension trial that will assess the long-term safety of aficamten in pediatric participants, and further assess efficacy and tolerability.
  3. Period 3 is the long-term extension trial that will assess the long-term safety of aficamten in pediatric participants, and further assess efficacy and tolerability.
03

Conditions studied

  • Pediatric
  • Symptomatic Obstructive Hypertrophic Cardiomyopathy

Keywords

  • CK-3773274
  • CK-274
  • Aficamten
  • Symptomatic Obstructive Hypertrophic Cardiomyopathy
  • oHCM
  • CEDAR
  • CEDAR-HCM
  • CY 6023
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Period 1: Treatment Period

    • Males and females between 12 and \< 18 years of age at screening and at Day 1.
    • Body weight ≥ 35 kg
    • Diagnosed with oHCM based on the following at screening:
  • Left ventricular (LV) hypertrophy with nondilated LV chamber in the absence of other cardiac disease.
  • Core laboratory confirmation of LV end-diastolic wall thickness that meets a threshold of:

    • Z-score > 2.5 in the absence of family history OR
    • Z-score > 2 in the presence of positive family history or positive genetic test.
  • Core laboratory confirmation of ≥ 60% AND Valsalva LVOT-G ≥ 50 mmHg.

    • oHCM of sarcomeric origin confirmed by genetic testing or, if unable to confirm by genetic testing, oHCM of sarcomeric origin may be presumed in the absence of history of metabolic disorders, mitochondrial cardiomyopathies, neuromuscular disease, malformation syndromes, infiltrative diseases/inflammation, and endocrine disorders (such as Fabry's disease, Noonan syndrome with left ventricular hypertrophy, and amyloid-cardiomyopathy).
    • (NYHA) Class ≥ II at screening.
    • Adequate acoustic windows for echocardiography.
    • Participants on beta blockers, verapamil, diltiazem, or disopyramide should have been on stable doses for more than 4 weeks prior to randomization.
  • Period 2: Open-Label Extension

    • Completed Period 1. If unable to complete Period 1 due to circumstances not related to compliance or safety, the Medical Monitor may review and determine eligibility.
    • LVEF ≥ 55% after washout
  • Period 3: Long-term Extension

    • Completed Period 2

Exclusion criteria

Exclusion Criteria:

  • Period 1: Treatment Period

Any of the following criteria will exclude potential participants from the trial:

  • Significant valvular heart disease.

    • Moderate or severe valvular aortic stenosis or fixed subaortic obstruction.
    • Mitral regurgitation that is greater than mild in severity and not due to systolic anterior motion of the mitral valve (per judgment of Principal Investigator or designee).
    • Evidence of fixed left-sided obstruction (eg, subaortic membrane, aortic valve stenosis, or coarctation of the aorta).
  • History of LV systolic dysfunction ( \< 45%) or stress cardiomyopathy at any time during their clinical course.
  • History of congenital heart disease other than oHCM (may be enrolled if not hemodynamically significant in the judgement of the Principal Investigator and study Medical Monitor).
  • Has been treated with SRT (surgical myectomy or percutaneous alcohol septal ablation) within the preceding 6 months or has plans for either treatment during the trial period.
  • History of paroxysmal or persistent atrial fibrillation or atrial flutter.
  • History of syncope, symptomatic ventricular arrhythmia, or sustained ventricular tachyarrhythmia within 3 months prior to screening.
  • History or evidence of any other disorder, , active infection, other condition, or disease that, in the opinion of the Principal Investigator (or designee) or the Medical Monitor, would pose a risk to participant safety or interfere with the trial evaluation, procedures, or completion.
  • Current or previous use of drugs known to cause cardiomyopathy (eg, anthracyclines, monoclonal antibodies [trastuzumab], alkylating agents [cyclophosphamide], and tyrosine kinase inhibitors [sunitinib and imatinib]).
  • Currently participating in another device or drug trial or received an investigational device or drug \< 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening.
  • Implantable cardioverter defibrillator (ICD) implantation within 6 weeks of screening or planned ICD implantation during the trial period.
  • Has received prior treatment with aficamten or mavacamten.
  • Currently listed for heart transplantation or anticipated to be listed for heart transplantation in the next 12 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
65 participants (estimated)

Study arms

  • Experimental
    Aficamten

    Participants in this arm will receive a single daily oral dose of aficamten with dose levels (5 mg to 20 mg) guided by echocardiography assessments, for 12 weeks during the double-blinded period, for another 52 weeks during the open-label extension period, and for an additional 144 weeks during the long-term extension period.

    Drug: Aficamten

  • Placebo comparator
    Placebo

    Participants in this arm will receive a single daily oral dose of placebo for 12 weeks during the double-blinded period and then will receive aficamten for 52 weeks during the open-label extension period, followed by an additional 144 weeks of aficamten during the long-term extension period.

    Drug: Aficamten · Drug: Placebo

Interventions

  • Oral Tablet

  • DrugPlacebo

    Oral Tablet

06

What researchers measure

Primary outcomes

  1. Change from baseline in Valsalva left ventricular outflow tract gradient (LVOT-G)

    Time frame: Baseline to week 12 (Period 1)

Secondary outcomes

  1. Change from baseline in resting LVOT-G

    Time frame: Baseline to week 12 (Period 1)

  2. Trough observed plasma concentration (Ctrough) and concentration 2 hours postdose of aficamten

    Time frame: Baseline to week 12 (Period 1)

  3. Change in values of N-terminal prohormone brain natriuretic peptide (NT-proBNP)

    Time frame: Baseline to week 12 (Period 1)

  4. Change in values of high sensitivity cardiac troponin I (hs-cTnI)

    Time frame: Baseline to week 12 (Period 1)

  5. Change in New York Heart Association (NYHA) Functional Class

    Time frame: Baseline to week 12 (Period 1), week 14 to week 66 (Period 2), and up to week 210 (Period 3)

  6. Change in peak LVOT-G

    Change in peak LVOT-G at rest and with valsalva provocation will be assessed at 12 week intervals during Period 2 and 24 week intervals during Period 3

    Time frame: Week 14 to week 66 (Period 2), and up to week 210 (Period 3)

  7. Proportion of participants with ≥1 class improvement in NYHA Functional Class

    Time frame: Baseline to week 12 (Period 1), week 14 to week 66 (Period 2), and up to week 210 (Period 3)

  8. Number of participants that have drug interruption or early discontinuation

    Time frame: Up to week 210

  9. Number of participants with appropriate implantable cardioverter defibrillator (ICD) discharges

    Time frame: Up to week 210

  10. Number of participants with left ventricular ejection fraction (LVEF) < 50%

    Time frame: Baseline to week 12 (Period 1), week 14 to week 66 (Period 2), and up to week 210 (Period 3)

  11. Number of participants with clinically significant changes in vital signs, 12-lead electrocardiogram (ECGs) and safety laboratory parameters

    Time frame: Up to week 210

  12. Proportion of participants with Valsalva LVOT-G < 50 mmHg

    Time frame: Week 14 to week 66 (Period 2), and up to week 210 (Period 3)

  13. Proportion of participants with Valsalva LVOT-G < 30 mmHg

    Time frame: Week 14 to week 66 (Period 2), and up to week 210 (Period 3)

  14. Time to first resting LVOT-G < 30 mmHg through last follow-up

    Time frame: Time to the following event through last follow-up, up to week 210

  15. Time to first valsalva LVOT-G < 50 mmHg through last follow-up

    Time frame: Time to event through last follow-up, up to week 210

  16. Time to first valsalva LVOT-G < 30 mmHg through last follow-up

    Time frame: Time to event through last follow-up, up to week 210

07

Study locations

36 sites
08

References and documents

Publications

  • Kaski JP, Kantor PF, Nakano SJ, Olivotto I, Russell MW, Godown J, Chiu M, German P, Heitner SB, Jacoby DL, Kupfer S, Lutz J, Maharao N, Malik FI, Melloni C, Nieto Morales PF, Simkins T, Wei J, Ho CY; CEDAR-HCM Investigators. Efficacy and Safety of Aficamten in Children and Adolescents With Obstructive Hypertrophic Cardiomyopathy: Study Design and Rationale of CEDAR-HCM. Circ Heart Fail. 2026 Feb;19(2):e013418. doi: 10.1161/CIRCHEARTFAILURE.125.013418. Epub 2025 Dec 5. PubMed 41347307 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Jan 2030, 68 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 14, 2024
StartActual
May 29, 2024
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06412666
Lead sponsor
Cytokinetics
Collaborators
Bayer
Responsible party
Sponsor
First posted
May 14, 2024
Start date
May 29, 2024
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Aug 18, 2026

Study contacts

Cytokinetics MD
study director · Cytokinetics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aficamten

Start the discussion